Introduction
Introduction Statistics Contact Development Disclaimer Help
.-') _ .-') _
( OO ) ) ( OO ) )
.-----. ,--./ ,--,' ,--./ ,--,'
' .--./ | \ | |\ | \ | |\
| |('-. | \| | )| \| | )
/_) |OO )| . |/ | . |/
|| |`-'| | |\ | | |\ |
(_' '--'\ | | \ | | | \ |
`-----' `--' `--' `--' `--'
lite.cnn.com - on gopher - inofficial
ARTICLE VIEW:
Major insurance changes are coming to GLP-1 drugs for weight loss.
Here’s how that could affect patients
By Deidre McPhillips, CNN
Updated:
9:16 AM EDT, Tue July 1, 2025
Source: CNN
Last week, Tara Eacobacci had an appointment with her doctor that was
devoted exclusively to the topic of health insurance. A major change to
her prescription benefits meant the medication she was using to manage
her weight – a treatment that had taken years of trial and error to
get right – would no longer be covered by insurance.
“I’m completely outraged,” Eacobacci said. “It’s not only
causing me stress, but it is making me angry.”
Starting Tuesday, CVS Caremark – a major pharmacy benefit manager
that serves as a middleman for health insurers, large employers and
other payers to manage their prescription drug plans – will stop
covering Eli Lilly’s Zepbound, a blockbuster GLP-1 drug that has been
approved by the US Food and Drug Administration since November 2023 for
chronic weight management in adults with obesity or who are overweight.
“This change is happening because there’s another covered
medication that’s safe and effective for your condition and may cost
less,” CVS Caremark said in a letter sent in May to its patients
using Zepbound. “Please keep in mind, if you refill your current
medication on or after 7/1/2025, you’ll need to pay the full cost.”
Wegovy, the GLP-1 medication to treat obesity from Lilly competitor
Novo Nordisk, will still be covered under plans managed by CVS
Caremark, along with a few other medications that are generally less
effective.
CVS says the decision to cover Wegovy and exclude Zepbound is
“forcing the drug manufacturers to compete with one another” and
will encourage both Eli Lilly and Novo Nordisk to lower prices for
their products in the US.
“The egregiously high list prices set by drug manufacturers of GLP-1s
for weight loss are the single biggest barrier to patient access,”
CVS Health said in a statement. “Our formulary strategy maintains
clinically appropriate coverage while using competition to drive lower
costs.”
But pharmacy benefit managers – of which CVS Caremark is one of the
largest – have faced for their role in rising drug costs in the US.
The coverage change applies to CVS Caremark’s most common formulary
template, which represents between 25 and 30 million individuals
overall. When the choice was available, the subset of members who take
weight-loss drugs chose Wegovy and Zepbound at roughly equivalent
levels, CVS Health said.
When it comes to weight loss, providers and patients argue that GLP-1
medications are not a one-for-one swap and that volatile insurance
coverage contradicts the science and experience of people managing
obesity as a chronic disease.
“Largely across society, we don’t accept obesity as a long-term
chronic disease, and we’re still looking for quick fixes and quick
solutions where that’s not the reality of the biology and disease
process. The mindsets have not caught up with the science yet,” said
Dr. Tracy Zvenyach, director of policy strategy and alliances at the
Obesity Action Coalition, a nonprofit advocacy group.
“If decision-makers do not understand obesity to be a long-term
chronic disease, that’s when we see these exclusionary policies or
these very, very cumbersome utilization management practices that
really just set up one barrier after another to prevent people from
getting the care that they need. It’s unacceptable. We don’t do
that with other chronic diseases.”
The trial-and-error system
It takes time to develop a treatment plan with GLP-1 drugs that works
with each individual patient, said Dr. Jody Dushay, an endocrinologist
at Beth Israel Deaconess Medical Center and assistant professor of
medicine at Harvard Medical School. Some people might have an allergic
reaction at the injection site for one medication or have worse side
effects – such as severe constipation, nausea or stomach pain –
with one than another.
Adapting to a change in medication will often interrupt a patient’s
weight-loss trajectory, she said, and the trial-and-error could create
a lot of waste for medications that were in shortage not long ago.
“As soon as these announcements [about insurance coverage changes]
come out, I get flooded with messages from patients,” she said.
“It’s very stressful for patients who have been doing really well,
who are having good tolerance and feel like they have hit their stride
in terms of medication, nutrition and exercise. Everything is heading
in the right direction, and then having to switch can be very
disruptive.”
When Dushay is looking through a patient’s medical chart, she says,
her stomach churns when she sees the little box that indicates their
insurance information.
“In this field of weight management, that little teeny part of the
chart dictates so much of their care. For me, it’s unprecedented in
terms of how much insurance matters for the clinical care that I’m
providing and the choices that I have,” she said.
And discussing strategies to manage insurance-mandated changes in
treatment infringes on clinical care.
“There is barely time to ask the patient how they are feeling, about
side effects and weight loss and general health updates,” Dushay
said. “There is a loss of time for patient care and a huge increase
in time burden outside the visit for doctors and pharmacists.”
Another major insurance change coming next year will affect another
large swath of Dushay’s patients: In January, BCBS Massachusetts will
be excluding all GLP-1s from coverage for treatment of obesity,
reserving coverage for these drugs only when indicated to treat type 2
diabetes.
“The nation is facing an obesity crisis. That’s why we work hard to
support our members achieve a healthy weight by improving access to
nutritious food, physical activity programs, and quality clinical care
when needed,” David Merritt, senior vice president of external
affairs for the Blue Cross Blue Shield Association, said in a
statement. “We share the enthusiasm for the real weight loss success
experienced by the countless patients taking GLP-1s. As with any new
medication, there is more to learn to ensure patients are set up for
success. Last year, we published a study that found of people do not
stay on GLP-1s long enough to see meaningful weight loss. While
adherence is , we need more data to ensure these costly medications
deliver long-term value for patients and the health care system.”
Doctors, patients frustrated
Zepbound and Wegovy are both effective at treating obesity and approved
by the FDA to do so, but there are differences.
Studies have found that people who used tirzepatide injections such as
Zepbound lost more weight and were more likely to reach specific weight
loss targets than those using semaglutide medications such as Wegovy.
The two drugs have a different set of broader indications, with
Zepbound also approved to treat sleep apnea in people with obesity, for
example. Side effects can vary, too, sometimes making one medication
more tolerable than the another.
People who have had success with Zepbound may be able to file for an
exception after the insurance coverage changes, but CVS Caremark has
limited options to proactively plan for the change, leaving many
patients angry and concerned about their health and well-being.
For Eacobacci, the insurance changes and the sentiment behind them are
enraging – and based in prejudice.
CVS Caremark had required that she try multiple alternate treatments
and prove that they didn’t work before she was approved for Zepbound
this year. When she was on Wegovy, she said, her A1C glucose levels
started to rise close to prediabetic levels despite consistent diet and
exercise habits. This all changed once she started Zepbound.
“I feel better. I’m not as bloated. My movement is definitely
different. I fit into my clothes, but I also feel validated – because
all of these years, doctors say to you, ‘Oh, you can’t eat all that
cake and candy,’ and they don’t believe that you’re not,”
Eacobacci said. “The medication actually validated some of this.
Like, ‘hey, I do need support. I can’t do this on my own as much as
I’m trying.’ ”
Medication changes could have unnecessarily dangerous impacts on
physical health – Eacobacci said she gained 10 pounds and saw her A1C
levels spike in just one month without the medication – as well as
mental health.
“Weight stigma and bias has affected us nationwide,” said
Eacobacci, who is worried about many people she knows who have felt
depressed after the hearing the news about changes in insurance
coverage. “You made me jump through hoops. I got the prior
authorization you required for me, and now you’re – mid-year –
taking it away from me is so impactful that it should be illegal.”
Although coverage exceptions may be an option, the appeals process
takes time.
“It gets really, really frustrating to have to justify what I want to
do all the time just because of money,” Dushay said.
For people who do lose coverage of Zepbound, drugmaker Eli Lilly has
expanded access through LillyDirect, a company platform that helps
coordinate telehealth services and fill prescriptions for patients who
pay out-of-pocket. Single-dose vials are available for $499 per month
through the LillyDirect Zepbound Self Pay Journey Program, with the
highest doses available beginning July 7.
“We’re confident in Zepbound’s performance and remain committed
to ensuring patients have access to the treatment they need,” Lilly
said in a statement.
<- back to index
You are viewing proxied material from codevoid.de. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.